Developmental and Epileptic Encephalopathy: Key Insights

Developmental and epileptic encephalopathies, commonly called DEEs, are a group of severe childhood-onset epilepsies in which both a genetic or structural brain abnormality and the seizure activity itself contribute to impaired development. That dual hit is what sets DEEs apart from milder forms of epilepsy: even if seizures could be fully controlled, many children would still face cognitive challenges because of the underlying cause, and the ongoing seizures make things worse. The term covers a wide spectrum of conditions, from Dravet syndrome and infantile spasms to Lennox-Gastaut syndrome, and the past decade of genetic research has reshaped how clinicians diagnose and, increasingly, treat them.

What Makes a DEE Different from Other Epilepsies

The phrase “developmental and epileptic encephalopathy” is intentionally layered. It captures two separate but overlapping problems. The “developmental” part means the underlying cause, often a gene variant, impairs brain development regardless of whether seizures occur. The “epileptic encephalopathy” part means the abnormal electrical activity from seizures and between seizures adds further developmental harm on top of whatever the gene itself has done. A child with a DEE therefore faces damage on two fronts simultaneously.

This matters because a child who has developmental delay and epilepsy does not automatically have a DEE. A purely developmental encephalopathy involves intellectual disability or motor delays that remain relatively stable over time, and while these children have a higher risk of epilepsy than the general population, the seizures do not necessarily worsen their cognitive trajectory further.¹ In contrast, the hallmark of a true DEE is that controlling seizure activity can partially improve development, while uncontrolled seizures visibly drive regression. An international classification effort led by the ILAE now formally separates self-limited epilepsy syndromes, where spontaneous remission is expected, from DEEs, where developmental impairment relates to both the underlying cause and the seizure burden.²

The Syndromes Under the DEE Umbrella

DEE is not a single condition. It is a category that includes several named syndromes, each with a characteristic age of onset, seizure type, and EEG pattern. Among the most recognized are infantile epileptic spasms syndrome (previously called West syndrome), Lennox-Gastaut syndrome, Dravet syndrome, and Ohtahara syndrome. A child can begin with one syndrome and evolve into another over months or years, which is one of the unsettling features of these conditions.

The transition from infantile spasms to Lennox-Gastaut syndrome is a well-documented example. In one study, about 36% of children with infantile spasms eventually met criteria for Lennox-Gastaut syndrome. Children at highest risk for this evolution were those who had developmental delay and seizures before the spasms even started, and those who responded poorly to the first treatment attempted for their spasms.³ Another cohort study found that evolution to Lennox-Gastaut syndrome took a median of roughly two years, with cases emerging not only from infantile spasms but also from other generalized, focal, or unclassified early-life epilepsies.⁴ Researchers are now exploring whether computational analysis of EEG connectivity patterns can detect this transition before the full clinical picture emerges, which could open a window for earlier intervention.⁵

Genetic Roots of DEEs

Advances in genetic sequencing have transformed the understanding of what causes DEEs. A large and growing number of single-gene variants can produce these conditions, and most arise as new mutations in the child rather than being inherited from carrier parents. The genes involved tend to encode proteins critical to how brain cells communicate: ion channels, synaptic machinery, and transcription factors that guide brain development.

Sodium channel genes are among the best-studied culprits. Three in particular, SCN1A, SCN2A, and SCN8A, account for a substantial share of genetic DEEs.⁶ SCN1A variants are the primary cause of Dravet syndrome, one of the best-known DEEs. More recently, SCN3A, which encodes a sodium channel subunit heavily expressed in the developing brain, has been linked to early infantile epileptic encephalopathy as well.⁷ Beyond sodium channels, variants in STXBP1, which encodes a protein involved in releasing chemical signals between neurons, have emerged as one of the more commonly identified genetic causes of neurological disorders as testing becomes more widespread.⁸

Even with modern sequencing, many children with a clinical DEE diagnosis receive no clear genetic answer. Multiple factors contribute to this gap, including mutations hiding outside the protein-coding parts of the genome, mosaic mutations present only in a fraction of cells, and the possibility that some cases involve the combined effects of more than one gene.⁹

How Seizures Injure the Developing Brain

The “epileptic encephalopathy” part of a DEE is not just about the visible seizures. Between seizures, the brain often produces bursts of abnormal electrical discharges called interictal spikes. When these spikes are frequent and widespread, they can interfere with learning and memory during waking hours and disrupt memory consolidation during sleep.¹⁰ In children whose brains are still wiring up foundational circuits, this constant electrical noise can derail development even when no obvious seizure is happening.

A specific form of this problem is seen in developmental and epileptic encephalopathy with spike-wave activation in sleep, a condition in which sleep-related electrical discharges surge during critical developmental windows and drive neurocognitive regression.¹¹ Sleep is when the young brain consolidates what it learned during the day, and flooding those hours with abnormal discharges can cause a child to lose skills they had previously acquired.

At the cellular level, many DEE-associated genes disrupt inhibitory brain cells called interneurons. These cells act as the brain’s braking system, preventing excitatory signals from spiraling out of control. Mutations in genes like ARX can impair the migration and development of these interneurons, a concept researchers call “interneuronopathy,” and this has been implicated in conditions like West syndrome and Ohtahara syndrome.¹² Animal models have shown that losing even one subtype of these inhibitory cells can produce spontaneous seizures and lasting changes in brain circuitry.¹³

Getting a Genetic Diagnosis

A genetic diagnosis matters because it can guide treatment, inform prognosis, and help families understand what happened. The practical question for most families is how likely genetic testing is to yield an answer. In a study of children with epilepsy who underwent various forms of sequencing, the overall diagnostic yield was about 33%, with epilepsy-focused gene panels performing somewhat better (around 40%) than broader whole-exome sequencing (around 28%).¹⁴ For children whose initial targeted gene panel comes back negative, moving to whole-exome sequencing can still pick up additional answers. One study of DEE patients with inconclusive panel results found that broader exome sequencing identified a clear causative variant in about 14% and a likely contributing variant in an additional subset.¹⁵

These numbers mean that more than half of children with DEEs still lack a genetic explanation after standard testing. Genome sequencing, which reads the entire DNA sequence including non-coding regions, is expected to close some of that gap, but interpreting variants outside of known genes remains challenging. For families, the practical takeaway is that a negative genetic test does not rule out a genetic cause; it may simply mean the technology has not caught up yet.

Treatment With Medications and Diet

DEEs are generally resistant to standard antiseizure medications, which is part of what makes them so devastating. Many children cycle through several drugs with limited success. But targeted options have been expanding.

Fenfluramine, a medication that works through serotonin and sigma-1 receptor pathways, is now approved in the United States for seizures associated with both Dravet syndrome and Lennox-Gastaut syndrome in children aged two and older, and as add-on therapy for these conditions in the EU, UK, and Japan.¹⁶ Clinical data suggest meaningful reductions in seizure burden and longer seizure-free intervals for both syndromes, though the evidence base is stronger for Dravet syndrome so far.¹⁷

The ketogenic diet, a high-fat, very-low-carbohydrate eating plan that shifts the brain’s fuel source, is one of the oldest treatments for drug-resistant epilepsy and remains particularly relevant in DEEs. In one study of children with severe epileptic encephalopathies, roughly a quarter became seizure-free and another quarter achieved at least a 50% reduction in seizures at twelve months on the diet.¹⁸ A more recent study focused specifically on genetically confirmed DEEs with onset before six months of age found even higher response rates during the maintenance phase: about 81% of patients had at least a 50% reduction in seizures, and roughly 38% achieved complete seizure freedom. Children with STXBP1 variants responded especially well, with four out of five becoming seizure-free. Side effects were mostly gastrointestinal and manageable, though one child stopped the diet due to kidney stones.¹⁹

Neuromodulation for Drug-Resistant Cases

When medications and diet fall short, device-based therapies can help reduce seizure burden. Vagus nerve stimulation, which delivers mild electrical pulses to a nerve in the neck, reduces seizures in roughly half of patients.²⁰ In a series specifically of patients with epileptic encephalopathies, those who responded well to vagus nerve stimulation showed improvements not only in seizure control but also in quality of life and neuropsychological performance, and the benefit tended to grow over time, continuing to improve up to three years of treatment.²¹

Deep brain stimulation is a more invasive option that targets specific structures within the brain. For generalized epilepsies such as Lennox-Gastaut syndrome, stimulation of a thalamic region called the centromedian nucleus has shown promise. These approaches do not cure the epilepsy, but for families dealing with dozens or hundreds of seizures per day, even partial reductions can meaningfully improve daily life.

Gene-Targeted Therapies on the Horizon

The growing ability to pinpoint the exact genetic cause of a DEE has opened the door to treatments aimed directly at the molecular defect, rather than broadly suppressing seizure activity. These precision approaches include antisense oligonucleotides (short pieces of synthetic genetic material designed to increase or decrease the output of a specific gene), gene replacement, and combined strategies.

For Dravet syndrome, where the problem is usually too little of the Nav1.1 sodium channel protein due to a loss-of-function SCN1A mutation, researchers have developed antisense oligonucleotides that boost production of the missing protein. In mouse models of Dravet syndrome, a single dose given early in life reduced seizures and dramatically improved survival. One study reported that 92% of treated mice survived to 90 days compared with 60% of untreated littermates.²² Follow-up work showed that the treatment restored the ability of inhibitory interneurons to fire normally and recovered their sodium current density to levels seen in healthy animals.²³ These results are still preclinical, but human trials are underway for related compounds.

For conditions caused by dominant-negative mutations, where the faulty copy of a gene actively interferes with the normal copy, a different strategy is needed. A “knockdown-and-replace” approach has been tested in mice with a DNM1 mutation that causes severe epilepsy. The strategy uses one tool to silence both copies of the gene and another to provide a fresh, functional copy. Neither component worked alone, but the combination allowed the vast majority of treated animals to survive with nearly full growth recovery.²⁴ The approach offers a conceptual template for other DEEs where simply adding back a working gene is not enough because the broken copy keeps causing harm.

The Risk of Sudden Unexpected Death

Sudden unexpected death in epilepsy, or SUDEP, is a real and frightening risk in DEEs, particularly in Dravet syndrome. The leading explanations involve seizure-triggered respiratory failure and fatal heart rhythm disturbances, with altered brainstem serotonin signaling also thought to play a role.²⁵ Genetic factors compound the risk. Patients with SCN1A-related Dravet syndrome face a markedly elevated risk, and variants in SCN2A and SCN8A, both primarily associated with DEEs, also contribute.²⁶ Risk-reduction strategies center on aggressive seizure control, particularly targeting generalized tonic-clonic seizures, and nighttime monitoring. For families, awareness of SUDEP risk is important not as a source of panic but as motivation to pursue effective seizure management and to discuss monitoring options with the care team.

What Happens as Children With DEEs Grow Up

DEEs do not stay static over a lifetime. A pattern often emerges: seizures tend to be most severe and frequent during infancy and early childhood, then gradually decrease in frequency as the child ages. That sounds like good news, but it comes with a painful trade-off. By the time seizures ease, many individuals have accumulated profound intellectual and motor disabilities. Some develop movement abnormalities resembling parkinsonism in adulthood. A small subset follows what appears to be a neurodegenerative course.²⁷

Predictors of worse long-term outcomes include earlier age at seizure onset, earlier need for antiseizure treatment, a history of status epilepticus, abnormal EEG background patterns, and a longer overall epilepsy duration. The transition from pediatric to adult care is a known weak point in the system: adult neurologists may have less experience with these rare childhood-onset conditions, and the shift in care teams can lead to treatment disruptions at a vulnerable time.

The Toll on Families and Caregivers

A conversation about DEEs that only covers biology and treatment is incomplete without acknowledging what these conditions do to families. Caring for a child with a DEE is all-consuming. In a survey of caregivers, quality of life varied enormously, ranging from what researchers categorized as an “ideal state” to a “high needs state.” The areas where caregivers most frequently reported unmet needs were pursuing activities they enjoy and looking after their own health. Interestingly, quality of life was most strongly tied to how caregivers emotionally perceived the illness and its consequences, rather than to health literacy or how activated they felt in their caregiving role.²⁸

This finding has practical implications. Support programs that target only factual education about the condition may miss the mark. What caregivers seem to need more is help reframing the emotional weight of the disease and reclaiming space for their own lives alongside the caregiving demands. Respite care, peer support groups, and mental health services are at least as important as medical information in sustaining families over the years and decades that DEE management requires.

Neuroimaging and Early Biomarkers

One of the frustrations with DEEs is that by the time seizures appear and a diagnosis is made, some developmental damage may already be underway. Researchers are working on identifying earlier biomarkers that could flag trouble before the clinical picture fully develops. In a mouse model carrying a KCNQ2 variant linked to DEE, longitudinal brain imaging revealed altered brain network maturation and abnormal synaptic density patterns compared to normal mice, with differences emerging at juvenile ages.²⁹ While translating findings from mice to human infants is never straightforward, this kind of work points toward a future in which at-risk children could be identified through imaging or other biomarkers before the most damaging phase of the encephalopathy sets in, potentially widening the window for gene-targeted therapies or other early interventions.